Total knee replacement with and without emicizumab: a unique comparison of perioperative management
Open Access
- 3 March 2020
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 4 (5) , 855-857
Abstract
Key Points: Prophylaxis with emicizumab was used in a patient with severe hemophilia with an inhibitor who underwent knee surgery. Use of emicizumab during surgery led to less recombinant factor VIIa and less bleeding, in addition to cost savings, for this patient.Keywords
This publication has 4 references indexed in Scilit:
- Emicizumab use in major orthopedic surgeryBlood Advances, 2019
- Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assaysTherapeutic Advances in Hematology, 2019
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without InhibitorsNew England Journal of Medicine, 2018
- Emicizumab Prophylaxis in Hemophilia A with InhibitorsNew England Journal of Medicine, 2017